Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Completed · Phase 3 · Has a placebo group

Conditions studied: Lateral Canthus Rhytides, Crow's Feet Lines

In brief

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).

Key facts

Study ID

NCT01189747

Run by

Allergan

People needed

446

Starts

2010-10-01

Expected to finish

2011-07-01

Last updated by the study team

2019-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe Crow's Feet Lines
• Have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses OK)

You may not qualify if…

• Current or previous botulinum toxin treatment of any serotype
• Facial laser or light treatment, microdermabrasion or superficial peels within 3 months
• Oral retinoid therapy within 1 year
• Prior facial cosmetic surgery (eg, periorbital surgery, facial lift, brow lift, eye lift, or eyebrow surgery)
• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis

Where it is running

• Study site — Newport Beach, California, United States
• Study site — Aalst, Belgium
• Study site — Vancouver, British Columbia, Canada
• Study site — Sutton Coldfield, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.